Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 3 December 2025

JPMorgan Chase (JPM) Stock Today: Near Record Highs, Q3 2025 Earnings Beat and 2026 Analyst Forecasts (3 December 2025)

JPMorgan Chase (JPM) Stock Today: Near Record Highs, Q3 2025 Earnings Beat and 2026 Analyst Forecasts (3 December 2025)

JPMorgan Chase & Co. (NYSE: JPM) continues to trade close to record levels as investors digest robust third‑quarter 2025 results, a massive $50 billion buyback program and a series of regulatory and macro headlines that could shape returns into 2026. As of December 3, 2025, JPMorgan’s share price hovers around $311 per share, after closing at $311.41 on Wednesday’s session.StockAnalysis This article summarizes all the key news, forecasts and analyses currently available as of 3 December 2025, and is intended for informational purposes only—not as personalized investment advice. 1. JPMorgan Chase stock snapshot as of December 3, 2025 Price and
3 December 2025
····
Applied Materials (AMAT) Stock Hits Record Highs on AI Chip Boom – Latest News, Analyst Targets and Forecasts as of December 3, 2025

Applied Materials (AMAT) Stock Hits Record Highs on AI Chip Boom – Latest News, Analyst Targets and Forecasts as of December 3, 2025

Applied Materials, Inc. (NASDAQ: AMAT) is trading around all‑time highs in early December 2025 as investors pile into “picks and shovels” plays on the artificial intelligence (AI) chip boom. The stock has surged more than 60% year to date and briefly touched a record level near $267 per share, even as new U.S. export controls on China and rich valuations spark warnings of a potential pullback. Investing.com Nigeria+1 Below is a detailed, Google‑News‑friendly rundown of today’s news, forecasts and analyses on AMAT stock as of December 3, 2025. Key facts about AMAT stock on December 3, 2025 Why AMAT is
3 December 2025
····
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven R&D milestones, and fresh analyst calls. StockAnalysis At the same time, investors are weighing sizable legal risks and an approaching patent cliff — making BMY one of the more eventful large‑cap healthcare stocks to watch into 2026. Below is a comprehensive, SEO‑friendly rundown of today’s Bristol-Myers Squibb stock news, forecasts, and analysis as of December 3, 2025. BMY Stock Price
3 December 2025
····
Exxon Mobil (XOM) Stock Today: UBS $145 Target, West Qurna Talks and 2026 Oil Glut Fears – December 3, 2025 Update

Exxon Mobil (XOM) Stock Today: UBS $145 Target, West Qurna Talks and 2026 Oil Glut Fears – December 3, 2025 Update

Exxon Mobil Corporation (NYSE: XOM) has entered December 2025 near the top of its 52‑week range, with fresh “Buy” ratings, a higher dividend, and a set of headline‑grabbing strategic moves that stretch from Texas to Iraq and Guyana. At the same time, Wall Street is warning that crude prices could be materially lower by 2026, putting the focus squarely on which oil majors can thrive in a mid‑cycle pricing world. As of intraday trading on December 3, 2025, Exxon Mobil stock is changing hands around $117.9 per share, up roughly 2.2% on the day, giving the company a market capitalization
3 December 2025
·····
AppLovin (APP) Stock Jumps on AI Adtech Momentum Despite SEC Probe – Latest News & Forecasts as of December 3, 2025

AppLovin (APP) Stock Jumps on AI Adtech Momentum Despite SEC Probe – Latest News & Forecasts as of December 3, 2025

AppLovin Corporation (NASDAQ: APP) is back in rally mode. As of Wednesday, December 3, 2025, the stock is trading in the mid‑$660s, up roughly 1–2% on the day and near recent highs after a powerful rebound from its October pullback.StockAnalysis Fueled by explosive growth in its AI‑driven Axon 2.0 advertising engine and fresh bullish analyst calls, APP is one of 2025’s standout tech winners — but the story is complicated by an ongoing SEC probe into its data‑collection practices and heavy insider selling. Below is a detailed look at today’s key news, forecasts, and analysis around AppLovin stock, curated from
3 December 2025
···
CoreWeave (CRWV) Stock After a 45% November Crash: Latest News, Analyst Forecasts and AI Cloud Outlook as of December 3, 2025

CoreWeave (CRWV) Stock After a 45% November Crash: Latest News, Analyst Forecasts and AI Cloud Outlook as of December 3, 2025

CoreWeave, Inc. (NASDAQ: CRWV) has become one of the most closely watched AI infrastructure stocks in 2025. After a spectacular run following its March IPO, the Nvidia‑backed GPU cloud provider is now grappling with a brutal drawdown, mounting debt, and growing debate over whether its valuation still makes sense. As of late trading on December 3, 2025, CoreWeave shares trade around the mid‑$70s (roughly $77, up about 1–2% on the day), well above the $40 IPO price but roughly 60% below their late‑June peak near $187. Yahoo Finance+1 Below is a detailed, SEO‑focused look at CoreWeave stock today – including
3 December 2025
····
Boeing (BA) Stock Today: Spirit AeroSystems Ruling, Cash-Flow Pledge and Airbus Troubles Move the Share Price – December 3, 2025

Boeing (BA) Stock Today: Spirit AeroSystems Ruling, Cash-Flow Pledge and Airbus Troubles Move the Share Price – December 3, 2025

Boeing Company (The) stock is back in the spotlight after a dramatic 10% surge on Tuesday and a fresh wave of regulatory and analyst headlines on December 3, 2025. Between a conditional green light for the Spirit AeroSystems takeover, upbeat cash‑flow guidance from the new CFO, and new problems at rival Airbus, investors are rapidly repricing Boeing’s long‑running turnaround story. Barron’s+3Reuters+3Reuters+3 Below is a detailed, Google‑News‑friendly rundown of today’s news, forecasts, and analysis impacting Boeing (BA) stock. 1. How Boeing Stock Is Trading on December 3, 2025 After soaring 10.15% on December 2 to a close of $205.38, Boeing shares
3 December 2025
·····
Pure Storage (PSTG) Stock Plunges After Q3 Earnings: What December’s Sell-Off Means for the AI Storage Leader

Pure Storage (PSTG) Stock Plunges After Q3 Earnings: What December’s Sell-Off Means for the AI Storage Leader

As of December 3, 2025, Pure Storage, Inc. (NYSE: PSTG) has gone from AI darling to one of the day’s biggest losers on Wall Street. After reporting strong third-quarter fiscal 2026 results, the all-flash data storage specialist saw its stock price collapse by roughly 26% to about $70, cutting deeply into gains that had left it near a 52‑week high above $100 earlier this week. StockAnalysis+1 Despite the violent reaction, the company’s fundamentals and analyst forecasts tell a more nuanced story—one that’s less about collapsing demand and more about valuation, margins, and the cost of chasing AI hyperscaler growth. What
3 December 2025
·····
C3.ai Stock (AI) on December 3, 2025: Earnings Day, Microsoft Tie-Up and Sale Rumors Put the Spotlight Back on This Volatile AI Name

C3.ai Stock (AI) on December 3, 2025: Earnings Day, Microsoft Tie-Up and Sale Rumors Put the Spotlight Back on This Volatile AI Name

C3.ai, Inc. (NYSE: AI) is back in the headlines today as the enterprise AI software company prepares to report fiscal Q2 2026 earnings after the closing bell. The stock has been crushed in 2025, is flirting with “special situation” territory, and yet sits at the center of some of the biggest themes in tech: generative AI, cloud partnerships, and a possible company sale. TipRanks+1 Below is a structured look at where C3.ai stands right now—its latest stock performance, Wall Street forecasts, technical picture, the new CEO, Microsoft partnership expansion, and what tonight’s earnings could mean next. Where C3.ai Stock Trades
3 December 2025
·····
Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Updated December 3, 2025 Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just turned into one of the wildest biotech stories of 2025. After the company reported positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel in Duchenne muscular dystrophy (DMD) early Wednesday, CAPR stock exploded from roughly $6.36 at Tuesday’s close to around $30 in Wednesday’s trading — a move of about +380%, with intraday highs near $40 and gains at one point exceeding +500%. BioPharma Dive At the same time, Wall Street analysts, regulators and patient advocates are rapidly reassessing both the approval odds and the long‑term
3 December 2025
····
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial, and Wall Street is suddenly a bit less euphoric about the stock. On December 3, Morgan Stanley cut Regeneron from Overweight to Equal Weight with a $767 price target, arguing that the shares now more or less reflect fair value and that future upside will depend on how clearly the company can execute on its pipeline. MarketScreener+1 At the same
3 December 2025
····
IREN Limited (IREN) Stock on 3 December 2025: Capital Raise, AI Cloud Supercycle and What Analysts Expect Next

IREN Limited (IREN) Stock on 3 December 2025: Capital Raise, AI Cloud Supercycle and What Analysts Expect Next

IREN Limited (NASDAQ: IREN) — the former Bitcoin miner now repositioned as an AI data‑center and cloud infrastructure player — is back in the spotlight on 3 December 2025 after unveiling a massive capital raise to fund its Microsoft AI deal and refinance older debt. At the same time, Wall Street’s forecasts for IREN point to big upside and big execution risk. Below is a detailed, SEO‑optimized rundown of the latest IREN stock news, forecasts, and analysis as of December 3, 2025. This article is for information only and is not financial advice. IREN stock today: price, performance and volatility
3 December 2025
·····
1 … 220 221 222 223 224 … 282

Stock Market Today

RELX share price slides again as AI fears linger, results next week in focus

RELX share price slides again as AI fears linger, results next week in focus

7 February 2026
RELX closed down 4.6% at 2,145 pence in London on Friday, capping a volatile week ahead of its Feb. 12 full-year results. The company bought back 465,361 shares even as selling continued amid investor concerns over AI risks and pricing power. Peers Wolters Kluwer and Thomson Reuters also faced pressure. Markets await RELX’s outlook for 2026 trading.
Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
Rio Tinto’s U.S. shares closed up 2.5% at $93.37 Friday after the company ruled out a merger with Glencore, triggering a six-month “no-bid” lockout under UK takeover rules. Both companies cited disagreements over valuation. Attention now turns to Rio’s Feb. 19 results and iron ore prices, which fell below $100 a tonne amid weak Chinese demand.
Go toTop